IciCLLe: Assessment of the Mechanism of Action of Ibrutinib (PCI-32765) in B-cell Receptor Pathway Inhibition in CLL.

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2013
This article has no abstract
Epistemonikos ID: a0d68e6c91f8d62e27df392e8634db52ba5e1576
First added on: Jan 22, 2025